• Explore /
  • Poster
  • / First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.

First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.

Abstract Poster

Authors

null

Jong-Mu Sun

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Jong-Mu Sun , Peter C. Enzinger , Antoine Adenis , Manish A. Shah , Ken Kato , Jaafar Bennouna , Toshihiko Doi , Natalyn Nicole Hawk , Li Yu , Sukrut Shah , Pooja Bhagia , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT04949256

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4167)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4167

Abstract #

TPS4167

Poster Bd #

149a

Abstract Disclosures

Similar Posters

First Author: Jong-Mu Sun

First Author: Deirdre Jill Cohen

First Author: Patricio Eduardo Yanez

First Author: Manish A. Shah